Showing 2631-2640 of 4067 results for "".
- First Patient Dosed in OYE Therapeutics IV Caffeine 505(b)(2) Bridging Studyhttps://reachmd.com/news/first-patient-dosed-in-oye-therapeutics-iv-caffeine-505b2-bridging-study/2486542/Key points: First patient dosed in a 505(b)(2) bridging study of OYE-101 OYE-101 is an intravenous caffeine formulation designed to accelerate recovery from anesthesia and deep sedation Study will generate human data to support a future 505(b)
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://reachmd.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- Rapid Fecal Calprotectin: CerTest card vs Actim and Calprest ELISAhttps://reachmd.com/news/rapid-fecal-calprotectin-certest-card-vs-actim-and-calprest-elisa/2486361/In patients clinically suspected of inflammatory bowel disease, a head-to-head evaluation compared rapid fecal calprotectin formats—including the CerTest Calprotectin one-step card, an Actim later
- Revance, Teoxane Introduce RHA® Dynamic Volume for Facial Rejuvenationhttps://reachmd.com/news/revance-teoxane-introduce-rha-dynamic-volume-for-facial-rejuvenation/2486353/Revance and Teoxane have announced the availability of RHA® Dynamic Volume, formerly known as RHA® 4 Mepi, expanding the RHA® Collection with a hyaluronic acid filler designed to adapt to facial movement and support natural-looking outcomes. The product has been approved by the US Food and Drug A
- New Hydrobiome Serum Targets Skin Barrier and Microbiome Balancehttps://reachmd.com/news/new-hydrobiome-serum-targets-skin-barrier-and-microbiome-balance/2486308/Epicutis has announced the launch of Hydrobiome Serum, a new addition to its clinical skincare portfolio developed in partnership with Signum Biosciences. The formulation is designed for patients with blemish-prone or congested skin and emphasizes microbiome balance and barrier support rather tha
- NDV‑01 Phase 2: 12‑Month CRs and Planned RESCUE Phase 3 Programhttps://reachmd.com/news/ndv01-phase-2-12month-crs-and-planned-rescue-phase-3-program/2486013/Relmada Therapeutics reported 12-month Phase 2 interim efficacy and tolerability findings for its sustained-release intravesical gemcitabine/docetaxel formulation NDV-01 in high-risk non-muscle invasive bladder cancer (NMIBC), alongside plans for a two-pathway Phase 3 RESCUE registrational
- Study Reports Improved Tolerability with Biomimetic Exosome Retinalhttps://reachmd.com/news/study-reports-improved-tolerability-with-biomimetic-exosome-retinal/2485852/A novel retinal formulation delivered via a biomimetic exosome platform was associated with significant clinical improvements in photodamaged skin without reported irritation, according to a 12-week study published in the Journal of Cosmetic Dermatology. In the single-center study
- The Rise of Biostimulators: Complement, Not Competitor, in Aesthetic Regimenshttps://reachmd.com/news/the-rise-of-biostimulators-complement-not-competitor-in-aesthetic-regimens/2485824/The filler category of medical aesthetics may have faced certain headwinds in 2025, but biostimulatory agents experienced a noticeable uptick. Still, at the 2026 Octane Aesthetics Tech Forum, “Flipping the Filler Script” panelists cautioned against viewing them as a replacement for hyaluronic aci
- Preclinical Nasal Spray Boosts Mucosal Defense and Blocks Allergic Responses in Micehttps://reachmd.com/news/preclinical-nasal-spray-boosts-mucosal-defense-and-blocks-allergic-responses-in-mice/2485812/An intranasal formulation described as GLA-3M-052-LS+OVA was reported in a Stanford Medicine mouse study to “supercharge” airway and mucosal defenses, with the write-up describing bro
- Speed-Focused Cognitive Training With Booster Sessions Linked to Lower Dementia Diagnoses Over 20 Yearshttps://reachmd.com/news/speed-focused-cognitive-training-with-booster-sessions-linked-to-lower-dementia-diagnoses-over-20-years/2485634/Long-term follow-up data from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) study indicate that a specific form of cognitive training—speed of processing